The FTC's Stance On Generic Biologics

Law360, New York (July 9, 2009, 12:00 AM EDT) -- This year marks the 25th anniversary of the Hatch-Waxman Act in the United States, which created a pathway for generic drugs by means of an abbreviated version of a New Drug Application for small molecule drugs regulated by the Federal Food, Drug and Cosmetic Act.

However, no pathway currently exists in the United States for generic biologics, or "follow-on biologics" ("FOBs"), by means of an abbreviated version of a Biologics License Application ("BLA") for larger and more complex biological molecules regulated by the Public Health Service...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.